Condition: HR+/HER2- Early Breast Cancer · Sponsor: Institut fuer Frauengesundheit
The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.
This description comes directly from the study's public registry record.
Sponsor's study office · +49 15739466438 · studien@ifg-erlangen.de
Always discuss trial participation with your own doctor first.
| Department of Obstetrics and Gynaecology, Uniklinikum Erlangen | Erlangen, Bavaria, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07531693